These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20179215)

  • 1. Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab.
    Stern HM; Padilla M; Wagner K; Amler L; Ashkenazi A
    Clin Cancer Res; 2010 Mar; 16(5):1587-96. PubMed ID: 20179215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.
    Spierings DC; de Vries EG; Timens W; Groen HJ; Boezen HM; de Jong S
    Clin Cancer Res; 2003 Aug; 9(9):3397-405. PubMed ID: 12960128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.
    Wagner KW; Punnoose EA; Januario T; Lawrence DA; Pitti RM; Lancaster K; Lee D; von Goetz M; Yee SF; Totpal K; Huw L; Katta V; Cavet G; Hymowitz SG; Amler L; Ashkenazi A
    Nat Med; 2007 Sep; 13(9):1070-7. PubMed ID: 17767167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy.
    Leithner K; Stacher E; Wurm R; Ploner F; Quehenberger F; Wohlkoenig C; Bálint Z; Polachova J; Olschewski A; Samonigg H; Popper HH; Olschewski H
    Lung Cancer; 2009 Jul; 65(1):98-104. PubMed ID: 19081160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
    Liu X; Yue P; Zhou Z; Khuri FR; Sun SY
    J Natl Cancer Inst; 2004 Dec; 96(23):1769-80. PubMed ID: 15572759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
    Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J
    Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
    Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
    Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target.
    Uddin S; Hussain AR; Ahmed M; Abubaker J; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Bavi P; Al-Kuraya KS
    Am J Gastroenterol; 2009 Jul; 104(7):1790-801. PubMed ID: 19491830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Ceppi P; Novello S; Cambieri A; Longo M; Monica V; Lo Iacono M; Giaj-Levra M; Saviozzi S; Volante M; Papotti M; Scagliotti G
    Clin Cancer Res; 2009 Feb; 15(3):1039-45. PubMed ID: 19188177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of tumor necrosis factors and their receptors in nonsmall cell lung carcinoma.
    Tran TA; Kallakury BV; Ambros RA; Ross JS
    Cancer; 1998 Jul; 83(2):276-82. PubMed ID: 9669810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma.
    Sugita M; Geraci M; Gao B; Powell RL; Hirsch FR; Johnson G; Lapadat R; Gabrielson E; Bremnes R; Bunn PA; Franklin WA
    Cancer Res; 2002 Jul; 62(14):3971-9. PubMed ID: 12124329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
    Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
    Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas.
    Jalving M; de Jong S; Koornstra JJ; Boersma-van Ek W; Zwart N; Wesseling J; de Vries EG; Kleibeuker JH
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4350-6. PubMed ID: 16857810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
    Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
    Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer.
    Bria E; Visca P; Novelli F; Casini B; Diodoro MG; Perrone-Donnorso R; Botti C; Sperduti I; Facciolo F; Milella M; Cecere FL; Cognetti F; Mottolese M
    Eur J Surg Oncol; 2008 May; 34(5):593-8. PubMed ID: 17693049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker.
    Reimer TA; Anagnostopoulos I; Erdmann B; Lehmann I; Stein H; Daniel P; Dörken B; Rehm A
    BMC Cancer; 2005 May; 5():47. PubMed ID: 15904507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interference with netrin-1 and tumor cell death in non-small cell lung cancer.
    Delloye-Bourgeois C; Brambilla E; Coissieux MM; Guenebeaud C; Pedeux R; Firlej V; Cabon F; Brambilla C; Mehlen P; Bernet A
    J Natl Cancer Inst; 2009 Feb; 101(4):237-47. PubMed ID: 19211441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
    Jin H; Yang R; Fong S; Totpal K; Lawrence D; Zheng Z; Ross J; Koeppen H; Schwall R; Ashkenazi A
    Cancer Res; 2004 Jul; 64(14):4900-5. PubMed ID: 15256461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DR5 receptor mediates anoikis in human colorectal carcinoma cell lines.
    Laguinge LM; Samara RN; Wang W; El-Deiry WS; Corner G; Augenlicht L; Mishra L; Jessup JM
    Cancer Res; 2008 Feb; 68(3):909-17. PubMed ID: 18245494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.